Antiverse is revolutionizing the pharmaceutical industry with its cutting-edge discovery platform that enables the creation of highly specific antibodies against G protein-coupled receptors (GPCRs). With the ability to generate cells with 1 million receptors per cell and antibody libraries with high specificity, Antiverse's technology is tackling the challenging task of discovering antibodies against GPCRs. Led by founder Murat Tunaboylu and supported by a group of investors, including Kadmos Capital Ltd, Innospark Ventures, Development Bank of Wales, Deep Science Ventures, and Tensor Ventures., Antiverse is based in Cardiff, Wales. 

Their advisor, Gherici Hassaine, former CSO of Theranyx, has over 20 years of experience in developing stable cell lines for antibody discovery. Antiverse's AI-generated specific antibody libraries and focus on functional epitopes give them an edge in the industry. With deep sequencing and AI-based clustering, they are screening their target-specific libraries against cells with high receptor counts to produce a high number of binders. The future of pharmaceutical manufacturing looks promising with Antiverse's innovative technology